EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublications en collaboration avec des chercheurs de David Geffen School of Medicine at UCLA (6)
2023
-
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1992-1998
2021
-
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Annals of Oncology, Vol. 32, Núm. 7, pp. 881-895
2020
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
2018
-
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Annals of Oncology, Vol. 29, pp. ix164
-
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092